Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
Mass vaccination with a safe and effective vaccine may be the best way to control the COVID-19 pandemic. Heterologous prime-boost vaccination with the CoronaVac and AZD1222 vaccines may increase the immunogenicity elicited by either vaccine alone. This study sought to compare the immunogenicity of a...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2052525 |
| _version_ | 1797673205596422144 |
|---|---|
| author | Guy Cohen Pawornrath Jungsomsri Jirath Sangwongwanich Kriangkrai Tawinprai Taweegrit Siripongboonsitti Thachanun Porntharukchareon Kasiruck Wittayasak Nawarat Thonwirak Kamonwan Soonklang Gaidganok Sornsamdang Chirayu Auewarakul Nithi Mahanonda |
| author_facet | Guy Cohen Pawornrath Jungsomsri Jirath Sangwongwanich Kriangkrai Tawinprai Taweegrit Siripongboonsitti Thachanun Porntharukchareon Kasiruck Wittayasak Nawarat Thonwirak Kamonwan Soonklang Gaidganok Sornsamdang Chirayu Auewarakul Nithi Mahanonda |
| author_sort | Guy Cohen |
| collection | DOAJ |
| description | Mass vaccination with a safe and effective vaccine may be the best way to control the COVID-19 pandemic. Heterologous prime-boost vaccination with the CoronaVac and AZD1222 vaccines may increase the immunogenicity elicited by either vaccine alone. This study sought to compare the immunogenicity of a heterologous CoronaVac and AZD1222 prime-boost with a homologous CoronaVac prime-boost. From July 13 to September 2, 2021, 88 participants were enrolled in the study. Half (n = 44) of the participants were assigned to the AZD1222/CoronaVac cohort and half were assigned to the CoronaVac/AZD1222 cohort. Both cohorts had a prime-boost interval of 4 weeks. A control group of 136 health care personnel who received the homologous CoronaVac/CoronaVac prime-boost was matched by age and sex to the experimental cohorts. The primary endpoint was the geometric mean ratio (GMR) of the anti-receptor binding domain (RBD) antibody concentration 4 weeks after the booster dose was administered. The CoronaVac/CoronaVac cohort served as the reference group. Baseline age and sex were similar, and the median age was 42.5 years. The GMR was 2.58 (95% confidence interval [CI] 1.80–3.71) and 8.69 (95% CI 6.05–12.47) in the AZD1222/CoronaVac and CoronaVac/AZD1222 cohorts, respectively. Reactogenicity was similar following prime and booster doses with the same vaccine. Findings indicated that the heterologous CoronaVac and AZD1222 prime-boost combination elicited a more robust immune response than the homologous CoronaVac prime-boost. While both heterologous prime-boost combinations showed similar reactogenicity, the immunogenicity of the CoronaVac/AZD1222 cohort was higher, indicating that the order of prime-boost vaccine administration was important. |
| first_indexed | 2024-03-11T21:40:54Z |
| format | Article |
| id | doaj.art-ace75072a2284f9c82835fe675893969 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:40:54Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-ace75072a2284f9c82835fe6758939692023-09-26T13:19:06ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20525252052525Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccinesGuy Cohen0Pawornrath Jungsomsri1Jirath Sangwongwanich2Kriangkrai Tawinprai3Taweegrit Siripongboonsitti4Thachanun Porntharukchareon5Kasiruck Wittayasak6Nawarat Thonwirak7Kamonwan Soonklang8Gaidganok Sornsamdang9Chirayu Auewarakul10Nithi Mahanonda11Chulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyChulabhorn Royal AcademyMass vaccination with a safe and effective vaccine may be the best way to control the COVID-19 pandemic. Heterologous prime-boost vaccination with the CoronaVac and AZD1222 vaccines may increase the immunogenicity elicited by either vaccine alone. This study sought to compare the immunogenicity of a heterologous CoronaVac and AZD1222 prime-boost with a homologous CoronaVac prime-boost. From July 13 to September 2, 2021, 88 participants were enrolled in the study. Half (n = 44) of the participants were assigned to the AZD1222/CoronaVac cohort and half were assigned to the CoronaVac/AZD1222 cohort. Both cohorts had a prime-boost interval of 4 weeks. A control group of 136 health care personnel who received the homologous CoronaVac/CoronaVac prime-boost was matched by age and sex to the experimental cohorts. The primary endpoint was the geometric mean ratio (GMR) of the anti-receptor binding domain (RBD) antibody concentration 4 weeks after the booster dose was administered. The CoronaVac/CoronaVac cohort served as the reference group. Baseline age and sex were similar, and the median age was 42.5 years. The GMR was 2.58 (95% confidence interval [CI] 1.80–3.71) and 8.69 (95% CI 6.05–12.47) in the AZD1222/CoronaVac and CoronaVac/AZD1222 cohorts, respectively. Reactogenicity was similar following prime and booster doses with the same vaccine. Findings indicated that the heterologous CoronaVac and AZD1222 prime-boost combination elicited a more robust immune response than the homologous CoronaVac prime-boost. While both heterologous prime-boost combinations showed similar reactogenicity, the immunogenicity of the CoronaVac/AZD1222 cohort was higher, indicating that the order of prime-boost vaccine administration was important.http://dx.doi.org/10.1080/21645515.2022.2052525covid-19heterologous prime-boostvaccine combinationchadox1 ncov-19azd1222coronavacimmunogenicity |
| spellingShingle | Guy Cohen Pawornrath Jungsomsri Jirath Sangwongwanich Kriangkrai Tawinprai Taweegrit Siripongboonsitti Thachanun Porntharukchareon Kasiruck Wittayasak Nawarat Thonwirak Kamonwan Soonklang Gaidganok Sornsamdang Chirayu Auewarakul Nithi Mahanonda Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines Human Vaccines & Immunotherapeutics covid-19 heterologous prime-boost vaccine combination chadox1 ncov-19 azd1222 coronavac immunogenicity |
| title | Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines |
| title_full | Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines |
| title_fullStr | Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines |
| title_full_unstemmed | Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines |
| title_short | Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines |
| title_sort | immunogenicity and reactogenicity after heterologous prime boost vaccination with coronavac and chadox1 ncov 19 azd1222 vaccines |
| topic | covid-19 heterologous prime-boost vaccine combination chadox1 ncov-19 azd1222 coronavac immunogenicity |
| url | http://dx.doi.org/10.1080/21645515.2022.2052525 |
| work_keys_str_mv | AT guycohen immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT pawornrathjungsomsri immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT jirathsangwongwanich immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT kriangkraitawinprai immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT taweegritsiripongboonsitti immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT thachanunporntharukchareon immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT kasiruckwittayasak immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT nawaratthonwirak immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT kamonwansoonklang immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT gaidganoksornsamdang immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT chirayuauewarakul immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines AT nithimahanonda immunogenicityandreactogenicityafterheterologousprimeboostvaccinationwithcoronavacandchadox1ncov19azd1222vaccines |